Literature DB >> 17642816

Multicenter study to evaluate efficacy and irritation potential of benzoyl peroxide 4% cream in hydrophase base (Brevoxyl) in acne vulgaris.

S N Sawleshwarkar1, V Salgaonkar, C M Oberai.   

Abstract

In this multicenter, open, non-comparative study, the efficacy and irritation potential of 4% benzoyl peroxide cream in hydrophase base (Brevoxyl) was evaluated for the treatment of acne vulgaris. All evaluable patients (n=567) received treatment with 4% benzoyl peroxide cream in hydrophase base for six weeks. The investigators evaluated the patients at baseline and at 1,2,4 &6 weeks. Patients also rated their improvement and adverse effects. Doctor's assessment showed that at the end of 6'h week 85.6% had good to very good effect of the treatment. The profile of side effects observed by doctors revealed that 53.8% of total patients did not have any irritation whereas only 11.6% had moderate to severe irritation. 53.8% of patients did not report any irritation: 41.4% had some irritation whereas only 4.8% patients reported troublesome irritation. A satisfactory response was reported as ear;y as two weeks and most of the patients had a very satisfactory response after six weeks and were willing to continue the treatment. This supports the theory that the hydrophase formulation in 'Brevoxyl helped to enhance efficacy and decrease the irritation associated with use of benzoyl peroxide.

Entities:  

Year:  2003        PMID: 17642816

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN: 0378-6323            Impact factor:   2.545


  2 in total

1.  Over-the-counter Acne Treatments: A Review.

Authors:  Ashley Decker; Emmy M Graber
Journal:  J Clin Aesthet Dermatol       Date:  2012-05

2.  Efficacy and Safety of the Traditional Japanese Medicine Keigairengyoto in the Treatment of Acne Vulgaris.

Authors:  Kotaro Ito; Saori Masaki; Manabu Hamada; Tetsuo Tokunaga; Hisashi Kokuba; Kenji Tashiro; Ichiro Yano; Shinichiro Yasumoto; Shinichi Imafuku
Journal:  Dermatol Res Pract       Date:  2018-07-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.